Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBOT NASDAQ:NPCE NASDAQ:OM NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$2.47-2.0%$2.56$0.82▼$3.38$91.67M1.131.82 million shs1.25 million shsNPCENeuroPace$9.06-0.2%$12.40$5.45▼$18.98$297.81M1.93187,621 shs132,242 shsOMOutset Medical$17.42-1.0%$19.25$5.85▼$62.10$311.91M2.15156,165 shs319,110 shsTMCITreace Medical Concepts$5.65-2.4%$6.03$4.54▼$10.79$364.13M0.69486,087 shs183,571 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical-1.18%-4.55%+4.13%+1.20%+135.51%NPCENeuroPace-0.33%-10.72%-15.77%-15.85%+20.91%OMOutset Medical-2.76%-14.60%-7.07%+59.85%-73.51%TMCITreace Medical Concepts-1.03%-6.76%+6.43%-10.16%-31.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBOTMicrobot Medical2.3037 of 5 stars3.53.00.00.02.70.00.6NPCENeuroPace3.5917 of 5 stars3.53.00.00.03.34.20.6OMOutset Medical1.463 of 5 stars3.51.00.00.02.20.80.0TMCITreace Medical Concepts2.8658 of 5 stars3.22.00.00.03.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBOTMicrobot Medical 3.00Buy$9.00264.37% UpsideNPCENeuroPace 3.00Buy$17.0087.64% UpsideOMOutset Medical 3.00Buy$29.5069.35% UpsideTMCITreace Medical Concepts 2.33Hold$10.5286.14% UpsideCurrent Analyst Ratings BreakdownLatest MBOT, TMCI, NPCE, and OM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025OMOutset MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$37.005/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.605/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/ANPCENeuroPace$79.91M3.72N/AN/A$0.27 per share33.56OMOutset Medical$113.69M2.72N/AN/A$7.49 per share2.33TMCITreace Medical Concepts$209.36M1.70N/AN/A$1.81 per share3.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBOTMicrobot Medical-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)NPCENeuroPace-$27.14M-$0.840.00N/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)OMOutset Medical-$127.98M-$29.150.00∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.850.00N/AN/A-25.14%-48.69%-24.59%8/5/2025 (Estimated)Latest MBOT, TMCI, NPCE, and OM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/AMBOTMicrobot Medical-$0.08N/AN/AN/AN/AN/A8/12/2025Q2 2025NPCENeuroPace-$0.24N/AN/AN/A$23.08 millionN/A8/6/2025Q2 2025OMOutset Medical-$1.76N/AN/AN/A$29.40 millionN/A8/5/2025Q2 2025TMCITreace Medical Concepts-$0.28N/AN/AN/A$47.08 millionN/A5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBOTMicrobot MedicalN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBOTMicrobot MedicalN/A16.1916.19NPCENeuroPace2.466.635.70OMOutset Medical0.578.376.74TMCITreace Medical Concepts0.514.503.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBOTMicrobot Medical16.30%NPCENeuroPace78.83%OMOutset MedicalN/ATMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipMBOTMicrobot Medical4.74%NPCENeuroPace20.50%OMOutset Medical2.40%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableNPCENeuroPace17032.80 million26.08 millionOptionableOMOutset Medical52017.72 million17.30 millionNot OptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableMBOT, TMCI, NPCE, and OM HeadlinesRecent News About These CompaniesKornitzer Capital Management Inc. KS Sells 161,525 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI)July 16 at 6:54 AM | marketbeat.comTreace Medical Concepts, Inc. Common Stock (TMCI) - NasdaqJuly 9, 2025 | nasdaq.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Average Recommendation of "Hold" by AnalystsJuly 7, 2025 | marketbeat.comLisanti Capital Growth LLC Makes New $2.12 Million Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)June 29, 2025 | marketbeat.comTMCI Treace Medical Concepts, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) is favoured by institutional owners who hold 53% of the companyJune 21, 2025 | finance.yahoo.comAttention Long-Term Treace Medical Concepts, Inc. (™CI) Shareholders: Grabar Law Office is Investigating Claims on Your BehalfJune 13, 2025 | investing.comKuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law FirmJune 11, 2025 | prnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025June 10, 2025 | accessnewswire.comATreace Medical Concepts, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff MotionJune 10, 2025 | globenewswire.comSecurities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents ShareholdersJune 10, 2025 | accessnewswire.comATMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 10, 2025 | globenewswire.comLost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & KorsinskyJune 10, 2025 | accessnewswire.comAClass Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & KorsinskyJune 10, 2025 | globenewswire.comTMCI DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 10, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalJune 10, 2025 | businesswire.comDid You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi & Korsinsky Urges Investors to Act Before June 10, 2025June 10, 2025 | accessnewswire.comAFINAL REMINDER TMCI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Treace Medical Concepts, Inc. Investors to Participate in the Class Action LawsuitJune 10, 2025 | accessnewswire.comALevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCIJune 10, 2025 | prnewswire.comShareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & KorsinskyJune 9, 2025 | accessnewswire.comATMCI FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 9, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBOT, TMCI, NPCE, and OM Company DescriptionsMicrobot Medical NASDAQ:MBOT$2.47 -0.05 (-1.98%) Closing price 04:00 PM EasternExtended Trading$2.53 +0.06 (+2.43%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.NeuroPace NASDAQ:NPCE$9.06 -0.02 (-0.22%) Closing price 04:00 PM EasternExtended Trading$9.12 +0.05 (+0.61%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Outset Medical NASDAQ:OM$17.42 -0.18 (-1.02%) Closing price 04:00 PM EasternExtended Trading$17.74 +0.31 (+1.81%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Treace Medical Concepts NASDAQ:TMCI$5.65 -0.14 (-2.42%) Closing price 04:00 PM EasternExtended Trading$5.72 +0.07 (+1.31%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
